Lyell Immunopharma (LYEL) Interest Expenses (2020 - 2026)
Lyell Immunopharma (LYEL) posted Interest Expenses of $58.7 million for Q1 2026, up 243.5% sequentially from $17.1 million in Q4 2025, and down 17.76% YoY from $71.4 million in Q1 2025.
Lyell Immunopharma (LYEL) Interest Expenses (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Interest Expenses for 7 years, with the latest figure at $58.7 million in Q1 2026.
- Quarterly Interest Expenses fell 17.76% year-over-year to $58.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.7 million (down 17.76% YoY) and the FY2025 annual result came in at $17.1 million, down 95.25% from the prior year.
- Interest Expenses climbed to $58.7 million in Q1 2026 per LYEL's latest filing, from $17.1 million in the prior quarter.
- Over five years, Interest Expenses peaked at $359.4 million in Q4 2024 and troughed at $1.2 million in Q4 2022.
- A 5-year average of $84.6 million and a median of $68.2 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses tumbled 99.08% in 2022, then jumped 21114.35% in 2023.
- Over 5 years, Interest Expenses stood at $1.2 million in 2022, then surged by 21114.35% to $248.4 million in 2023, then soared by 44.69% to $359.4 million in 2024, then plunged by 95.25% to $17.1 million in 2025, then soared by 243.5% to $58.7 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $58.7 million, $17.1 million, and $65.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 55.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.45 Mn |
| Jun 30, 2026 | 55.45 Mn |
| Mar 31, 2026 | 58.70 Mn |
| Mar 31, 2026 | 58.70 Mn |
| Dec 31, 2025 | 17.09 Mn |
| Dec 31, 2025 | 17.09 Mn |
| Sep 30, 2025 | 65.06 Mn |
| Sep 30, 2025 | 65.06 Mn |
| Jun 30, 2025 | 68.23 Mn |
| Jun 30, 2025 | 68.23 Mn |
| Mar 31, 2025 | 71.38 Mn |
| Mar 31, 2025 | 71.38 Mn |
| Dec 31, 2024 | 359.44 Mn |
| Dec 31, 2024 | 359.44 Mn |
| Sep 30, 2024 | 75.06 Mn |
| Sep 30, 2024 | 75.06 Mn |
| Jun 30, 2024 | 77.96 Mn |
| Jun 30, 2024 | 77.96 Mn |
| Mar 31, 2024 | 19.02 Mn |
| Mar 31, 2024 | 19.02 Mn |